Orchard Therapeutics Stock Forecast, Price & News

Orchard Therapeutics (NASDAQ:ORTX) Frequently Asked Questions

Is Orchard Therapeutics a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Orchard Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Orchard Therapeutics stock.
View analyst ratings for Orchard Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Orchard Therapeutics?

Wall Street analysts have given Orchard Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Orchard Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Orchard Therapeutics' next earnings date?

Orchard Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 2nd 2021.
View our earnings forecast for Orchard Therapeutics.

How were Orchard Therapeutics' earnings last quarter?

Orchard Therapeutics plc (NASDAQ:ORTX) announced its quarterly earnings results on Wednesday, August, 4th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.03.
View Orchard Therapeutics' earnings history.

How has Orchard Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Orchard Therapeutics' stock was trading at $9.08 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ORTX shares have decreased by 79.2% and is now trading at $1.89.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for ORTX?

4 Wall Street analysts have issued 12 month price targets for Orchard Therapeutics' stock. Their forecasts range from $12.00 to $17.00. On average, they anticipate Orchard Therapeutics' stock price to reach $13.75 in the next twelve months. This suggests a possible upside of 627.5% from the stock's current price.
View analysts' price targets for Orchard Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Orchard Therapeutics' key executives?

Orchard Therapeutics' management team includes the following people:

• Bobby Gaspar, Chief Executive Officer & Executive Director
• Frank E. Thomas, President, COO, CFO & Chief Accounting Officer
• Andrea Spezzi, Chief Medical Officer
• Ran Zheng, Chief Technical Officer
• Nicoletta Loggia, Chief Technical Officer

Who are some of Orchard Therapeutics' key competitors?

Some companies that are related to Orchard Therapeutics include Agenus (AGEN), ImmunityBio (IBRX), Scholar Rock (SRRK), Tenaya Therapeutics (TNYA), Sutro Biopharma (STRO), Forma Therapeutics (FMTX), Vaxart (VXRT), Mesoblast (MESO), Immatics (IMTX), Adaptimmune Therapeutics (ADAP), Graphite Bio (GRPH), Curis (CRIS), Aligos Therapeutics (ALGS), Osiris Therapeutics (OSIR) and Talaris Therapeutics (TALS).
View all of ORTX's competitors.

What other stocks do shareholders of Orchard Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Orchard Therapeutics investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP), Entasis Therapeutics (ETTX), (NGM), Selecta Biosciences (SELB) and VBI Vaccines (VBIV).

When did Orchard Therapeutics IPO?

(ORTX) raised $200 million in an IPO on Wednesday, October 31st 2018. The company issued 13,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Orchard Therapeutics' stock symbol?

Orchard Therapeutics trades on the NASDAQ under the ticker symbol "ORTX."

How do I buy shares of Orchard Therapeutics?

Shares of ORTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Orchard Therapeutics' stock price today?

One share of ORTX stock can currently be purchased for approximately $1.89.

How much money does Orchard Therapeutics make?

Orchard Therapeutics has a market capitalization of $236.95 million and generates $2.60 million in revenue each year. The company earns $-151.98 million in net income (profit) each year or ($1.53) on an earnings per share basis.

How many employees does Orchard Therapeutics have?

Orchard Therapeutics employs 2,020 workers across the globe.

What is Orchard Therapeutics' official website?

The official website for Orchard Therapeutics is www.orchard-tx.com.

Where are Orchard Therapeutics' headquarters?

Orchard Therapeutics is headquartered at 108 CANNON STREET, LONDON X0, EC4N 6EU.

How can I contact Orchard Therapeutics?

Orchard Therapeutics' mailing address is 108 CANNON STREET, LONDON X0, EC4N 6EU. The company can be reached via phone at 442038088286.